These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12569562)

  • 1. Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model.
    Breeman WA; Mearadji A; Capello A; Bernard BF; van Eijck CH; Krenning EP; de Jong M
    Int J Cancer; 2003 Apr; 104(3):376-9. PubMed ID: 12569562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
    Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
    Swärd C; Bernhardt P; Johanson V; Schmitt A; Ahlman H; Stridsberg M; Forssell-Aronsson E; Nilsson O; Kölby L
    Cancer Biother Radiopharm; 2008 Feb; 23(1):114-20. PubMed ID: 18298335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro.
    Capello A; Krenning EP; Breeman WA; Bernard BF; Konijnenberg MW; de Jong M
    Cancer Biother Radiopharm; 2003 Oct; 18(5):761-8. PubMed ID: 14629824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor gene therapy combined with targeted therapy with radiolabeled octreotide: a new treatment for liver metastases.
    Mearadji A; Breeman W; Hofland L; van Koetsveld P; Marquet R; Jeekel J; Krenning E; van Eijck C
    Ann Surg; 2002 Dec; 236(6):722-8; discussion 728-9. PubMed ID: 12454510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.
    de Jong M; Breeman WA; Bakker WH; Kooij PP; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt MA; Erion JL; Bugaj JE; Mäcke HR; Krenning EP
    Cancer Res; 1998 Feb; 58(3):437-41. PubMed ID: 9458086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.
    Melis M; Forrer F; Capello A; Bijster M; Bernard BF; Reubi JC; Krenning EP; De Jong M
    Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):324-33. PubMed ID: 17923824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
    de Jong M; Breeman WA; Valkema R; Bernard BF; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():13S-7S. PubMed ID: 15653647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.
    Breeman WA; van der Wansem K; Bernard BF; van Gameren A; Erion JL; Visser TJ; Krenning EP; de Jong M
    Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):312-5. PubMed ID: 12552352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
    Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
    Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
    Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
    J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.
    Rolleman EJ; Forrer F; Bernard B; Bijster M; Vermeij M; Valkema R; Krenning EP; de Jong M
    Eur J Nucl Med Mol Imaging; 2007 May; 34(5):763-771. PubMed ID: 17146655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
    Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
    Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
    Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model.
    Lewis JS; Laforest R; Lewis MR; Anderson CJ
    Cancer Biother Radiopharm; 2000 Dec; 15(6):593-604. PubMed ID: 11190491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver.
    Slooter GD; Breeman WA; Marquet RL; Krenning EP; van Eijck CH
    Int J Cancer; 1999 May; 81(5):767-71. PubMed ID: 10328231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
    Bodei L; Pepe G; Paganelli G
    Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibitory effect of (111)In-DTPA(0)-octreotide on intrahepatic tumor growth after partial hepatectomy.
    Slooter GD; Aalbers AG; Breeman WA; Hiemstra CA; Marquet RL; Krenning EP; van Eijck CH
    J Nucl Med; 2002 Dec; 43(12):1681-7. PubMed ID: 12468520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.